Memo. Implications of Proposed Rule on Medicare Part D Protected Class
|
|
- Vivian Price
- 5 years ago
- Views:
Transcription
1 Memo Implications of Proposed Rule on Medicare Part D Protected Class March 11, 2019
2 I. Introduction Since the implementation of Medicare Part D in 2006, six classes of drugs have been protected to ensure patients with certain chronic conditions would not face discrimination or interruptions accessing their drugs. 1-3 As such, private insurance plans who participate in Part D are required to cover all immunosuppressant, antidepressant, antipsychotic, anticonvulsant, antiretroviral, and antineoplastic drugs. 2 In November 2018, however, the Centers for Medicare and Medicaid Services (CMS) announced a proposed rule aimed at reducing prescription drug prices for Medicare beneficiaries. The rule includes three provisions that could compromise protection for drugs in the six classes. As proposed, Part D prescription drug plans could: (1) increase their use of utilization management practices such as step therapy and prior authorization for protected class drugs; (2) exclude a protected class drug from its formulary if the drug represents a new formulation of an existing drug; and (3) exclude a protected class drug if its price increases exceed a standard rate of inflation over a specified time period. Antiretrovirals are unique among the protected classes in that they treat and prevent HIV, an infectious disease. In contrast, the other protected class drugs are indicated for noncommunicable diseases. Therefore, access restrictions would have serious public health implications both for infected patients and those at risk of infection. 4 At present, only half of patients with HIV have reduced viral loads, highlighting the need for strategies that facilitate, not restrict, treatment access. 4 Adherence to antiretroviral therapy (ART) is necessary to reduce viral load and disease transmission. Accordingly, current treatment guidelines recommend the use of tailored and patient-centered treatment, which inherently requires comprehensive treatment options. 4 This is especially true of patients with HIV who may be covered by Medicare Part D, as this population has a higher burden of comorbidities and other treatment considerations. 4 Restricted access or increased cost of treatment may cause patients to stop adhering to their treatment regimen, impacting these patients ability to maintain low viral loads. Additionally, newer innovative HIV treatments provide extensive patient benefits such as reduced adverse events and the potential to improve adherence (single-tablet regimens). For example, tenofovir alafenamide (TAF), can reduce the risks of bone loss and renal toxicity, which is especially important for older patients with HIV. 5 Further, it is provided in single-tablet regimens (STRs), which have been associated with better adherence than multi-tablet regimens (MTRs). 6 In this memo, we assess the potential impacts of the three Part D proposed rule provisions on patients with HIV. Analyses conducted for this memo are based on results from a previously-published model by Baumgardner et al., 2018, which estimated the impacts of restrictive formularies for patients with HIV. 7 That study examined how restricting access among innovative ART (measured through a series of formulary access scenarios) would affect the occurrence and cost of adverse events, as well as deaths attributable to sub-optimal disease management. The most restrictive scenario required patients to stay on a tenofovir disoproxil (TDF) regimen for the duration of their care, whereas the open formulary scenario resulted in a substantial number of patients initiating treatment on the more recently introduced TAF therapy, allowed for switching of patients to TAF therapy if adverse events or treatment failure occurred, and also had a more optimal matching of patients to TDF, TAF and abacavir / dolutegravir / lamivudine (Triumeq), depending on baseline patient characteristics. The step therapy scenario initiated all patients on TDF and allowed them to switch to TAF or another treatment after the occurrence of a renal or bone adverse event or other treatment failure. For purposes of this memo, the results of the model by Baumgardner et al., 2018 were scaled to a population representing patients with HIV in care who are insured through - 1 -
3 II. III. Medicare (25% of the US population with HIV in care). 8 Results are presented for a 10-year time horizon beginning in 2020 (when the proposed rule would go into effect). Implications of the utilization management provision Utilization management practices, like step therapy and prior authorization, aim to reduce drug costs by requiring patients to initiate on less expensive therapies before they can access more expensive specialty ones. 9 It can affect timely access to treatment, reduce adherence and/or lead to avoidable adverse events. 7,10 As such, the current Medicare Part D Manual notes that, for HIV treatment, prior authorization and step therapy are generally not employed in widely used, best practice formulary models. 11 Applying the model of Baumgardner et al. to the Medicare population suggests that the utilization management provision in the proposed rule could result in 7,200 additional allcause deaths and 84,000 more renal and bone adverse events from 2020 through 2029 if patients were subjected to step therapy, compared to a policy with no access restrictions to treatment. The cost of these adverse events would be approximately $1.08 billion higher (in discounted 2020 dollars 12 ). Those additional costs include all the medical care used to treat the additional bone and renal adverse events including costs of inpatient hospital, office-based provider, outpatient hospital, prescription drugs, and emergency department care. Further, this provision could lead to over 6,750 new HIV infections from increased viral loads among Medicare patients with HIV. Those 6,750 additional infections would be transmitted from the Medicare population but the new cases would be distributed across the general population meaning that those new patients who received treatment and were insured would have various sources of coverage including private payers, Medicaid, and Medicare. Implications of the drug formulation and drug pricing provisions Both of these provisions could have the impact of eliminating a drug (or possibly a number of drugs) from a formulary if it did not meet the requirements. Drug formulation is especially important for HIV therapies, as single-tablet regimens (STRs), compared with multi-tablet regimens (MTRs), have been associated with greater retention in care and treatment efficacy. 13 Other research has shown that STRs are associated with a lower risk of hospitalization, compared with MTRs. 6 Further, by completely restricting access to some HIV treatments through these provisions, patients who develop drug resistance may no longer have viable treatment options. Evidence also has suggested patients treated with newer ART regimens may be less susceptible to drug resistance, which further highlights the benefits of broad access to novel ARTs. 14 Based on the model of Baumgardner et al., restrictions that made TAF-based ART unavailable, akin to what could occur if the provisions on drug formulation and drug pricing were implemented, could lead to 8,000 additional all-cause deaths and 87,600 additional renal and bone adverse events between 2020 and 2030, compared to open access treatment. The incremental cost of these adverse events would be over $1.1 billion from 2020 through Lastly, restricting access to TAF could lead to over 7,600 new infections from as a result of increased viral loads from use of suboptimal therapies among patients with HIV. The potential effect of the three proposed Part D rule changes together are likely quite similar to the estimates in this section of the memo, that is, it would not be correct to add the numbers in sections II and III of this memo. As is evident, most of the negative consequences of the combined proposal come from the potential elimination of treatments with high efficacy and low adverse event rates from the first line of treatment, which can happen under both step therapy designs and under provisions that could eliminate a drug from the formulary. Thus, - 2 -
4 IV. the vast majority of the costs of the full proposal would arise from greater use of step therapy alone. Conclusion Broad access to ART is important for patients with HIV to ensure adherence, reduce viral load, and prevent disease transmission and avoidable adverse events. In addition to the potential impacts on patients, there are a number of social and political implications of the proposed rule. Broader use of utilization management could enable Part D plans to engage in discriminatory practices by using these practices to deter patients with HIV from enrolling in their plans. 15 Further, the drug pricing provision could lead to an increase in launch prices of drugs in the protected classes in order to avoid being removed from formularies if market conditions suggested future price increases. 16 Lastly, the risk of additional, and preventable, HIV infections may be greater as a result of the proposed rule if patients are unable to access therapies that will maximize their adherence and reduce their viral load or if individuals at risk of HIV are unable to access PrEP. 17 While the protected class status is important for the six categories of drugs, the preventive and treatment benefits of ART necessitate policies that promote, and do not restrict, comprehensive treatment access. Sources of Support: Precision Health Economics (PHE), which provides consulting services to life sciences and other industries. At the time of this study J. Baumgardner, C. Huber and J. Chou were employees of PHE. Financial support for the study was provided by Gilead Sciences to - 3 -
5 References 1. Administration Proposes Strategies To Lower Pharmaceutical Prices In Medicare Part D. Health Affairs; Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit; Final Rule In: Department of Health and Human Services, ed. 42. Vol 400, 403, 411, 417, The Pew Charitable Trusts. Policy Proposal: Revising Medicare's Protected Classes Policy. March 7, US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV Sangarlangkarn A, Appelbaum JS. Caring for Older Adults with the Human Immunodeficiency Virus. Journal of the American Geriatrics Society. 2016;64(11): Scott Sutton S, Magagnoli J, Hardin JW. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016;36(4): Baumgardner J, Huber C, Kabiri M, Yoon L, Chou J, Romley J. Modeling the impacts of restrictive formularies on patients with HIV. The American journal of managed care. 2018;24(8 Spec No.):SP322-SP The Henry J. Kaiser Family Foundation. Medicare and HIV Lotvin AM, Shrank WH, Singh SC, Falit BP, Brennan TA. Specialty medications: traditional and novel tools can address rising spending on these costly drugs. Health Affairs. 2014;33(10): American Academy of HIV Medicine. Prior Authorization. Washington D.C Centers for Medicare & Medicaid Services. Chapter 6- Part D Drugs and Formulary Requirements. In: Department of Health and Human Services, ed. Medicare Prescription Drug Benefit Manual Centers for Medicare & Medicaid Services. Market Basket Definitions and General Information. Reports/MedicareProgramRatesStats/Downloads/info.pdf. Accessed Flash CA, Carter J, Giordano TP, Zerai T. Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naïve patients AU - Hemmige, Vagish. AIDS Care. 2018;30(8): Feder AF, Rhee S-Y, Holmes SP, Shafer RW, Petrov DA, Pennings PS. More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. Elife. 2016;5:e Jacobs DB, Sommers BD. Using drugs to discriminate adverse selection in the insurance marketplace. New England Journal of Medicine. 2015;372(5): Duggan M, Scott Morton FM. The distortionary effects of government procurement: evidence from Medicaid prescription drug purchasing. The Quarterly Journal of Economics. 2006;121(1): Castel AD, Magnus M, Greenberg AE. Update on the Epidemiology and Prevention of HIV/AIDS in the USA. Current epidemiology reports. 2015;2(2):
HIV: The Great Debate On Clinical Approach Vs. Cost Considerations
M E D I C A ID H E A L T H P L A N S O F AMERICA HIV: The Great Debate On Clinical Approach Vs. Cost Considerations Steve Miller, MD Chief Medical Officer October 2018 HIV IMPACT: 1.1M Americans affected
More informationGuidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017
Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017 Scottish Health Protection Network HIV Clinical Leads FINAL Approved for circulation 17 May 2017 Version No. 6.2 (04/05/17) Date
More informationApurba Chakraborty MBBS, MPH Dima M. Qato PharmD, MPH, PhD Professor Mark S. Dworkin MD, MPHTM The University of Illinois at Chicago
Less is More: The Impact of Lower Pill Burden on Adherence to Antiretroviral Therapy among Treatment-Naive Patients with HIV Infection in the United States Apurba Chakraborty MBBS, MPH Dima M. Qato PharmD,
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION ELVITEGRAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE (Genvoya Gilead Sciences Canada, Inc.) Indication: HIV-1 Infection Recommendation:
More informationClinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals
Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University
More informationPERSPECTIVE THERXPIPELINE
ON PERSPECTIVE THERXPIPELINE Understanding changes in the medication market and their impact on cost and care. EnvisionRx continuously monitors the drug pipeline. As treatment options change, we evaluate
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationIssues for Part D Compliance
HCCA- MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE Issues for Part D Compliance Craig Miner, RPh, JD Division of Drug Plan Policy Babette S. Edgar, Pharm.D., MBA Division of Finance and Operations
More informationMedicaid in South Carolina. South Carolina Medicaid in /19/2018. > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1.
Medicaid in South Carolina > FY 2017 Appropriation: $7.2 billion > Full benefit Membership: 1.04 million South Carolina Medicaid in 2018 Bryan Amick SC Chapter, American Academy of Pediatrics 2018 CATCH
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationClinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents
Clinical Commissioning Policy Proposition: Tenofovir Alafenamide for treatment of HIV 1 in adults and adolescents Reference: NHS England F03X08 First published: Month Year Prepared by NHS England Specialised
More informationDefinition. Synonyms 9/23/2010. Trials for which the hypothesis and study design are formulated based on information needed to make a decision
Scott Ramsey, MD, PhD Definition Trials for which the hypothesis and study design are formulated based on information needed to make a decision Synonyms Pragmatic clinical trials Practical clinical trials
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationRe: Impact of Prohibiting HIV Prescription Drug Co-pay Cards from Counting Towards Deductibles and Maximum Out-of-Pocket Expenses
May 16, 2018 Name Address Re: Impact of Prohibiting HIV Prescription Drug Co-pay Cards from Counting Towards Deductibles and Maximum Out-of-Pocket Expenses Dear : We the 60 undersigned organizations of
More informationThe New HIV Epidemic Challenges: Policy, Politics, and Poor Patients
The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients John T. Carlo, MD, MS Chief Executive Officer AIDS ARMS, INC. https://twitter.com/jtcarlo Conflict of Interest None 2 Learning Objectives
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationUp to $402,000. Insight HIV. Drug Class. 1.2 million people in the United States were living with HIV at the end of 2011 (most recent data).
HIV Background, new developments, key strategies Drug Class Insight INTRODUCTION Human Immunodeficiency Virus (HIV) is the virus that can lead to Acquired Immunodeficiency Syndrome, or AIDS. No safe and
More information05/01/2014. Medicare has 4 parts A: Hospital coverage National Training Program. Session Objectives. The Basics. B: Outpatient medical coverage
2015 National Training Program Medicare Prescription Drug Coverage Parts A, B and D Session Objectives This session should help you Differentiate when/under what scenarios drugs are covered under the various
More informationAdvaMedDx Value Assessment Framework in Practice
AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody
More informationState of Alabama AIDS Drug Assistance Program (ADAP) Quarterly Report
State of Alabama AIDS Drug Assistance Program (ADAP) Quarterly Report This report reflects active clients currently enrolled in ADAP Full-pay Prescription Program (ADAP-Rx), Alabama s Insurance Assistance
More informationDr Marta Boffito. Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000:
BHIVA AUTUMN CONFERENCE 2013 Including CHIVA Parallel Sessions Dr Marta Boffito Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Dr Marta Boffito Statement
More informationINTERNAL QUESTIONS AND ANSWERS DRAFT
WHO CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION Background: INTERNAL QUESTIONS AND ANSWERS DRAFT At the end of 2012, 9.7 million people were receiving
More information2
1 2 3 4 5 6 7 8 9 ADAP client enrollment and client utilization reached their highest levels during FY2010. However, as a result of the national fiscal crisis and implementation of cost-containment measures,
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationPatient Input CADTH COMMON DRUG REVIEW. darunavir/cobicistat/emitrictabine/tenofovir alafenamide (Symtuza) (Janssen Inc.) Indication: HIV-1 infection
CADTH COMMON DRUG REVIEW Patient Input darunavir/cobicistat/emitrictabine/tenofovir alafenamide (Symtuza) (Janssen Inc.) Indication: HIV-1 infection CADTH received patient input for this review from: Canadian
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationFunding the Ryan White Program: Now and in the Future
Funding the Ryan White Program: Now and in the Future Carl Schmid United States Conference on AIDS San Diego, CA October 4, 2014 Outline The Fiscal Environment Recent Ryan White Funding Levels Impact of
More informationTHE GROWTH OF SPECIALTY PHARMACY
UnitedHealth Center for Health Reform & Modernization THE GROWTH OF SPECIALTY PHARMACY Current trends and future opportunities Issue Brief April 2014 Summary Innovative specialty drugs are providing important
More informationReportback from the 2013 ICAAC in Denver, CO
Information, inspiration and advocacy for people with HIV/AIDS and hepatitis C p1 p3 p8 PrEP NEWS New tenofovir vaginal ring protects monkeys, PrEP uptake higher among women and young people. HIV CARE
More informationHealth Care Reform Update and Advocacy Priorities
Health Care Reform Update and Advocacy Priorities Robert Greenwald Clinical Professor of Law Director, Center for Health Law and Policy Innovation of Harvard Law School October 2012 PRESENTATION OUTLINE
More informationTHE AFFORDABLE CARE ACT AND HIV MAXIMIZING OPPORTUNITIES FOR COVERAGE AND CARE
THE AFFORDABLE CARE ACT AND HIV MAXIMIZING OPPORTUNITIES FOR COVERAGE AND CARE Jeffrey S. Crowley Distinguished Scholar/Program Director, National HIV/AIDS Initiative O Neill Institute for National and
More informationEconomic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G
Economic analysis of initial HIV treatment: efavirenz- versus indinavir-containing triple therapy Caro J J, O'Brien J A, Miglaccio-Walle K, Raggio G Record Status This is a critical abstract of an economic
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV
ViiV Healthcare s Position on Continuous Innovation in Prevention, Testing, Treatment & Care of HIV ViiV Healthcare is a company 100% committed to HIV, and we are always looking to move beyond the status
More informationDidactic Series. Update on DHHS Guidelines for HIV Treatment: Adherence to the Care Continuum
Didactic Series Update on DHHS Guidelines for HIV Treatment: Adherence to the Care Continuum Daniel Lee, MD UCSD Medical Center Owen Clinic March 8 th, 2018 1 Adherence to the Care Continuum Revised from
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationNASTAD AT-A-GLANCE. Britten Pund, Director, Health Care Access
NASTAD AT-A-GLANCE Britten Pund, Director, Health Care Access ABOUT NASTAD 2 WHO, WHAT, AND HOW Who is NASTAD? Leading non-partisan non-profit association representing public health officials who administer
More informationIs current first line ART good enough? Francois Venter Wits Reproductive Health & HIV Research Institute
Is current first line ART good enough? Francois Venter Wits Reproductive Health & HIV Research Institute Results: by April 2011 Budget: $3.5 billion 80% of 3,686 health facilities providing ARVs 50% ARV
More informationThe new epidemic of drug resistant HIV-1
The new epidemic of drug resistant HIV-1 Gillian Hunt Centre for HIV and STI National Institute for Communicable Diseases ICREID March 2018 Status of the global HIV epidemic (2016) WHO Global Summary on
More informationTHE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT. Esteban Burrone Head of Policy
THE MEDICINES PATENT POOL APPROACH TO SCALE UP ACCESS TO HIV AND HCV TREATMENT Esteban Burrone Head of Policy LEARNING FROM THE HIV RESPONSE EVOLUTION OF AIDS DRUG PRICES: 2000-2008 Source: MSF (2008)
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Diagnosis and promotion of serostatus awareness in sub-saharan Africa 1. Antiretroviral therapy reduces HIV transmission from a HIV- positive person to a susceptible
More informationPatient Forecasts for Pipeline ARVs: Adults
Patient Forecasts for Pipeline ARVs: Adults Presented at: WHO/UNAIDS Annual Meeting with ARV Manufacturers and Stakeholders March 19-20, 2015 Vineet Prabhu Market Intelligence Team, CHAI HIV Access Program
More informationSelect the Print Complete Record, Add to Basket or Record Buttons to print the record, to add it to your basket or to the record.
Skip to Main Content Main Menu Back to National Coverage Determinations (NCDs) Alphabetical Index Select the Print Complete Record, Add to Basket or Email Record Buttons to print the record, to add it
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationtargets for HIV-positive children
Accessing antiretroviral therapy (ART) is a matter of life and death for HIV-infected children. Without ART, half of children born with HIV die by the age of two years, and 80 percent die by the age of
More informationResponse to HIV LOGISTICAL AND OTHER PERSPECTIVES
Response to HIV LOGISTICAL AND OTHER PERSPECTIVES Margaret Brandeau Department of Management Science and Engineering Department of Medicine Stanford University Topics HIV: A humanitarian crisis Planning
More informationREPORT OF THE COUNCIL ON MEDICAL SERVICE
REPORT OF THE COUNCIL ON MEDICAL SERVICE CMS Report -I- Subject: Presented by: Referred to: Hearing Aid Coverage (Resolutions -I- and -I-) Robert E. Hertzka, MD, Chair Reference Committee J (Jeffrey P.
More informationShaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact
Shaping our future: a call to action to tackle the diabetes epidemic and reduce its economic impact Task Force for the National Conference on Diabetes: The Task Force is comprised of Taking Control of
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationEXPRESSION OF INTEREST New Horizons Advancing Pediatric HIV Care Donation Program
EXPRESSION OF INTEREST New Horizons Advancing Pediatric HIV Care Donation Program Background With the release of the 2014 UNAIDS 90-90- 90 treatment target, programs are expected to scale- up efforts to
More informationQUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE
CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,
More informationOverview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014
AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING Overview of 2013 WHO consolidated ARV guidelines and update plans Marco Vitoria HIV/AIDS Department WHO Geneva September 2014 AMDS ANNUAL STAKEHOLDERS AND
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationmedicaid and the The Role of Medicaid for People with Diabetes
on medicaid and the uninsured The Role of for People with Diabetes November 2012 Introduction Diabetes is one of the most prevalent chronic conditions and a leading cause of death in the United States.
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationKEEP LOVING. Because HIV doesn t change who you are.
KEEP LOVING. Because HIV doesn t change who you are. BIKTARVY is a complete, 1-pill, once-a-day prescription medicine used to treat HIV-1 in certain adults. BIKTARVY does not cure HIV-1 or AIDS. Please
More informationEvidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February For public consultation
Evidence Review: Comparison between tenofovir alafenamide and tenofovir disoproxil fumarate. February 2016 - NHS England Evidence Review: Comparison of tenofovir alafenamide and tenofovir disoproxil fumarate.
More informationNEXT GENERATION DIRECT-ACTING ANTIVIRALS
EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS-1: THE EXPEDITION-2 STUDY J. Rockstroh, K. Lacombe, R. Viani, C. Orkin, D.
More informationAn Examination of Access to HIV/AIDS Medications in Exchange Plans United States Conference on AIDS. September 10,
An Examination of Access to HIV/AIDS Medications in Exchange Plans United States Conference on AIDS September 10, 2015 www.avalere.com Agenda PlanScape Methodology Key Takeaways Access to HIV/AIDS Medications
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationDEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA
DEFENSE HEALTH AGENCY 7700 ARLINGTON BOULEVARD, SUITE 5101 FALLS CHURCH, VIRGINIA 22042-5101 DHA-IPM 18-020 MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (MANPOWER AND RESERVE AFFAIRS) ASSISTANT SECRETARY
More informationRestrictions to HCV Treatment in State Medicaid Programs
Center for Health Law and Policy Innovation of Harvard Law School Restrictions to HCV Treatment in State Medicaid Programs Acknowledgements: We are in the midst of merging/comparing data with other analysts
More informationDescovy. (emtricitabine, tenofovir alafenamide) New Product Slideshow
Descovy (emtricitabine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Descovy Generic name: Emtricitabine, tenofovir alafenamide (TAF) Pharmacological class: Nucleoside analog reverse
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More information2017 Drug Trend Report Commercial Medicare Medicaid Exchanges
2017 Drug Trend Report Commercial Medicare Medicaid Exchanges Leading the way for patients and plans Our clients place a great deal of trust in Express Scripts. They ask us to care for their plan members
More informationBest Practices for Specialty Pharmacy Usage Management. Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC
Best Practices for Specialty Pharmacy Usage Management Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC Overview Provide a background to specialty pharmacy Identify key industry
More informationApril 20, 2016 TESTIMONY OF PATRICK BEATTY, ESQ.
April 20, 2016 TESTIMONY OF PATRICK BEATTY, ESQ. On behalf of Equitas Health, and the Ohio AIDS Coalition, we thank the Joint Committee on Medicaid Oversight for the opportunity to offer testimony regarding
More informationMedicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment
American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trogarzo) Reference Number: CP.PHAR.378 Effective Date: 04.17.18 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationFIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES
FIXED DOSE COMBINATION: CLINICAL & PHARMACEUTICAL PERSPECTIVES Cape Winelands Anova Conference 2013 Worcester Lindsay Wilson 3 June 2013 What is a fixed dose combination [FDC]? Pharmaceutical formulation
More informationKey Messages for World Malaria Day 2009
INFORMATION RBM/WG/2009/INF.12 10 APR 2009 Draft document General distribution English Only Key Messages for World Malaria Day 2009 Counting Malaria Out to Reaching the 2010 Targets On the occasion of
More informationThe cost-effectiveness of raising the legal smoking age in California Ahmad S
The cost-effectiveness of raising the legal smoking age in California Ahmad S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each
More informationMedical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum
Medical Challenges of HIV/AIDS pandemic: The WHO perspective SOLTHIS HIV Forum Marco Vitoria HIV/AIDS Department World Health Organization September 2013 Topic 2002 2003 2006 2010 2013 When to start 1
More informationImplementation of testing (and other interventions along the Continuum of Care)
Implementation of testing (and other interventions along the Continuum of Care) Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control
More informationMeasure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction
Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationhiv/aids Programme Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants
hiv/aids Programme Programmatic update Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants EXECUTIVE SUMMARY April 2012 EXECUTIVE SUMMARY Recent developments
More informationPreparing for Potential Game Changers
Long-Acting HIV Treatment and Prevention Are Coming July 2018 The Foundation for AIDS Research Innovative products for treating and preventing HIV infection are under development. Sometimes called long-acting
More informationCan we make first line ART better?
Can we make first line ART better? Dr Angela Hartwig 8 th SA AIDS Conference, Durban Skills Building Session 15 June 2017 With thanks to Francois Venter and the people who gave him slides Characteristics
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV infection (all ages) Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationMedication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More information2016 NYS HIV Quality of Care Review
2016 NYS HIV Quality of Care Review A new way forward in four parts Bruce Agins, MD, MPH Medical Director NYSDOH AIDS Institute December 15, 2016 Ending the Epidemic: update! A 3-Point plan announced by
More informationEXECUTIVE SUMMARY ENSURING PATIENT ACCESS TO SAFE, EFFECTIVE AND AFFORDABLE PRESCRIPTION MEDICINES // 2
EXECUTIVE SUMMARY Prescription drugs play a critical role in helping to prevent, manage and cure various conditions and diseases. Today, ground-breaking medicines are profoundly improving the conditions
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationHow are Adult Immunizations paid for in the United States?
How are Adult Immunizations paid for in the United States? Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization Summit February
More informationInsurance Coverage Changes for People with HIV Under the ACA
Insurance Coverage Changes for People with HIV Under the ACA Jennifer Kates, Lindsey Dawson Prior to the Affordable Care Act (ACA), people with HIV faced limited access to insurance coverage due to several
More informationAddressing Prescription Drug Abuse. Allan Coukell Senior Director, Drugs and Medical Devices The Pew Charitable Trust
Addressing Prescription Drug Abuse Allan Coukell Senior Director, Drugs and Medical Devices The Pew Charitable Trust Outline 1. Prescription Drug Monitoring Programs 2. Federal policy landscape including
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More informationMODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM
MODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM MODULE 3 SERVICE NEEDS FOR HIV-INFECTED INDIVIDUALS There are compelling personal and public health benefits to getting
More informationVaccine Coverage Requirements in the U.S.
Vaccine Coverage Requirements in the U.S. Richard Hughes IV and Emily Sobel 10.18.17 Avalere Health T 202.207.1300 avalere.com An Inovalon Company F 202.467.4455 1350 Connecticut Ave, NW Washington, DC
More informationTowards universal access
Key messages Towards universal access Scaling up priority HIV/AIDS interventions in the health sector September 2009 Progress report Towards universal access provides a comprehensive global update on progress
More informationPatient Input CADTH COMMON DRUG REVIEW. doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) (Merck Canada Inc.) Indication: HIV Infection
CADTH COMMON DRUG REVIEW Patient Input doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) (Merck Canada Inc.) Indication: HIV Infection CADTH received patient input from: Canadian Treatment
More information